Autres langues Regeneron Pharmaceuticals, Inc.

Actions

REGN

US75886F1075

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 30/09/2026			Varia. 5j.	Varia. 1 janv.
758,27 ^USD	+1,03%		-5,43%	-1,76%

09:00	Bourse : BNP met le cap au nord, Sanofi rempile avec Regeneron, Alstom engrange
08:52	Sanofi paie au moins 1 milliard de dollars à Regeneron pour le Dupixent	AW

Autres langues

08:29	Sanofi : accordo da 1 mld $ con Regeneron per sviluppo nuovi anticorpi
08:08	Sanofi und Regeneron erweitern Allianz in Milliardendeal
07:50	Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion
07:28	Sanofi, Regeneron Expand Immunology Partnership in Up to $8 Billion Deal
07:01	Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
07:00	Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
00:31	Regeneron weight-loss drug halves muscle loss in combination with Novo's semaglutide in trial
00:02	Regeneron drug halves muscle loss in combination with Novo's semaglutide in trial
30/09	Major drugmakers turn to China for licensing deals
29/09	Regeneron Needs 'Better' Terms in Sanofi Renegotiation, RBC Says
29/09	Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026
28/09	Pfizer's Tilrekimig Phase 3 Program Seen as Potential Upside Driver, UBS Says
28/09	Biohaven Ltd. And Regeneron Pharmaceuticals, Inc. Enter Into Clinical Supply Agreement For BHV-1530 And Cemiplimab
28/09	Major drugmakers turn to China for licensing deals
28/09	US drugmakers turn to China for licensing deals
25/09	US FDA approves Mirum's drug for rare bone disorder
24/09	Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026
24/09	Regeneron Approaching Incremental Catalysts Like Upcoming Olatorepatide Data Readout, RBC Says
21/09	Telix to Buy Germany's ITM Isotope in Deal Worth Up to $2.35 Billion
10/09	MONDAY REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
10/09	Regeneron Pharmaceuticals More Likely to Retain Eylea HD Patent, RBC Says
08/09	MONDAY REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before September 14, 2026 Deadline - RGRD Law
04/09	SEPTEMBER 14, 2026 REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
02/09	Compañías que se deben tener muy en cuenta por técnico este miércoles en Wall Street
02/09	Valores destacados al cierre del mercado norteamericano